Endocrinology News

The FDA approved the SGLT2 inhibitor dapagliflozin to improve glycemic control among children and adolescents aged 10 years and older with type 2 diabetes, according to an industry press release.

BOSTON — Evidence suggests hyperandrogenism is associated with changes in the gut microbiome in women with polycystic ovary syndrome and the gut microbiome may play a causal role in PCOS metabolic dysregulation, according to a speaker.

BOSTON — Midlife women reporting bothersome hot flashes are more likely to receive a diagnosis of metabolic dysfunction-associated steatotic liver disease regardless of hormone therapy use, according to a speaker.

PHILADELPHIA — In this Healio video exclusive, Deepak L. Bhatt, MD, MPH, discusses two hot topics in cardiometabolic medicine: icosapent ethyl and sotagliflozin.

The AMA adopted new policies on broader Medicare and Medicaid health care coverage during its annual House of Delegates meeting.

PHILADELPHIA — Consistently missed periods brought on by intense exercise, disordered eating or stress in young women can lead to multiple consequences, including endothelial dysfunction and increased CVD risk, according to a speaker.

BOSTON — People with primary ovarian insufficiency have higher risk for breast cancer and borderline increased risk for ovarian cancer compared with the general population, and risks for some cancers extend to their relatives, data show.

The AMA announced a new policy that supports requirements for drug and device sponsors to develop diversity action plans so that women and sexual and gender minorities are adequately represented in their clinical trials.

PHILADELPHIA — Adults with Cushing’s syndrome who responded to relacorilant had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial.

BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.